Beyond cervical cancer: burden of other HPV-related cancers among men and women.

[1]  Anna Trakoli.  IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 99: Some Aromatic Amines, Organic Dyes, and Related Exposures. International Agency for Research on Cancer , 2012 .

[2]  R. Biggar,et al.  Risk of human papillomavirus-associated cancers among persons with AIDS. , 2009, Journal of the National Cancer Institute.

[3]  N. Weiss,et al.  Is the incidence of invasive vulvar cancer increasing in the United States? , 2009, Cancer Causes & Control.

[4]  B Romanowski,et al.  Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women , 2009, The Lancet.

[5]  J. Palefsky,et al.  The epidemiology of anal human papillomavirus and related neoplasia. , 2009, Obstetrics and gynecology clinics of North America.

[6]  Melanie A. Williams,et al.  Understanding the burden of human papillomavirus‐associated anal cancers in the US , 2008, Cancer.

[7]  A. Giuliano,et al.  Incidence of in situ and invasive vulvar cancer in the US, 1998–2003 , 2008, Cancer.

[8]  S. Coughlin,et al.  Burden of potentially human papillomavirus‐associated cancers of the oropharynx and oral cavity in the US, 1998–2003 , 2008, Cancer.

[9]  A. Giuliano,et al.  Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. , 2008, The Journal of infectious diseases.

[10]  C. Tsien,et al.  EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Goldie,et al.  The economic burden of noncervical human papillomavirus disease in the United States. , 2008, American journal of obstetrics and gynecology.

[12]  A. Chaturvedi,et al.  Underestimation of relative risks by standardized incidence ratios for AIDS-related cancers. , 2008, Annals of epidemiology.

[13]  A. Cmelak,et al.  Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. , 2008, Journal of the National Cancer Institute.

[14]  A. Chaturvedi,et al.  Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Bingshu E. Chen,et al.  Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. , 2007, Journal of the National Cancer Institute.

[16]  P. Castle,et al.  A Comparison of Cervical and Vaginal Human Papillomavirus , 2007, Sexually transmitted diseases.

[17]  E. Taioli,et al.  Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: Review and meta‐analysis , 2007, International journal of cancer.

[18]  J. Pow-Sang,et al.  Incidence trends in primary malignant penile cancer. , 2007, Urologic oncology.

[19]  D. Lowy,et al.  Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. , 2007, JAMA.

[20]  M. Gillison,et al.  Current topics in the epidemiology of oral cavity and oropharyngeal cancers , 2007, Head & neck.

[21]  M. Falster,et al.  Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis , 2007, The Lancet.

[22]  Henry C Kitchener,et al.  Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial , 2007, The Lancet.

[23]  Daron G Ferris,et al.  Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. , 2007, The New England journal of medicine.

[24]  F. X. Bosch,et al.  Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions , 2007 .

[25]  Eduardo Lazcano-Ponce,et al.  Safety and Persistent Immunogenicity of a Quadrivalent Human Papillomavirus Types 6, 11, 16, 18 L1 Virus-Like Particle Vaccine in Preadolescents and Adolescents: A Randomized Controlled Trial , 2007, The Pediatric infectious disease journal.

[26]  L. Mariani,et al.  High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  D. Lowy,et al.  Prospects for cervical cancer prevention by human papillomavirus vaccination. , 2006, Cancer research.

[28]  R. Fleurence,et al.  Review of the economic and quality-of-life burden of cervical human papillomavirus disease. , 2006, American journal of obstetrics and gynecology.

[29]  F. Bray,et al.  Chapter 2: The burden of HPV-related cancers. , 2006, Vaccine.

[30]  D. Parkin,et al.  The global health burden of infection‐associated cancers in the year 2002 , 2006, International journal of cancer.

[31]  M. Gillison,et al.  Clinical implications of human papillomavirus in head and neck cancers. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  P. Judson,et al.  Trends in the Incidence of Invasive and In Situ Vulvar Carcinoma , 2006, Obstetrics and gynecology.

[33]  D. Rimm,et al.  Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  N. Schlecht.  Prognostic value of human papillomavirus in the survival of head and neck cancer patients: an overview of the evidence. , 2005, Oncology reports.

[35]  M. Gillison,et al.  Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. , 2004, Seminars in oncology.

[36]  S. Schwartz,et al.  Anal cancer incidence and survival: The Surveillance, Epidemiology, and End Results experience, 1973–2000 , 2004, Cancer.

[37]  C. R. Leemans,et al.  Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. , 2004, Journal of the National Cancer Institute.

[38]  Claude Fauquet,et al.  Classification of papillomaviruses. , 2004, Virology.

[39]  M. Sherman,et al.  Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976–2000 , 2004, Cancer.

[40]  S. Franceschi,et al.  Human Papillomavirus Type 16 and TP53 Mutation in Oral Cancer , 2004, Cancer Research.

[41]  A. Mocroft,et al.  Decline in the AIDS and death rates in the EuroSIDA study: an observational study , 2003, The Lancet.

[42]  K. Shah,et al.  Chapter 9: Role of mucosal human papillomavirus in nongenital cancers. , 2003, Journal of the National Cancer Institute. Monographs.

[43]  Karl Münger,et al.  Human papillomavirus immortalization and transformation functions. , 2002, Virus research.

[44]  J. Goedert,et al.  Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. , 2000, Journal of the National Cancer Institute.

[45]  D. Sidransky,et al.  Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. , 2000, Journal of the National Cancer Institute.

[46]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[47]  M. Lehtinen,et al.  Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. , 2009, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[48]  A. Giuliano,et al.  HEAD AND NECK SQUAMOUS CELL CANCER AND THE HUMAN PAPILLOMAVIRUS: SUMMARY OF A NATIONAL CANCER INSTITUTE STATE OF THE SCIENCE MEETING, , 2009 .

[49]  D. Lowy,et al.  Assessing the Burden of HPV-Associated Cancers in the United States HPV Prophylactic Vaccines and the Potential Prevention of Noncervical Cancers in Both Men and Women , 2008 .

[50]  A. Giuliano,et al.  Assessing the Burden of HPV-Associated Cancers in the United States , 2008 .